Psychotic Disorders: all 1,655 studies
Page 16 of 17. Open to participants first (298), then studies with results posted, then the rest; newest registration first within each.
- Switch Study of Existing Atypical Antipsychotics to BifeprunoxCompletedNCT00347425Phase 3
- Seroquel STACK Study in Schizophrenic or Schizoaffective SubjectsCompletedNCT00328978Phase 3
- Sarcosine (N-Methylglycine) Monotherapy for SchizophreniaCompletedNCT00328276Phase 2
- Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.CompletedNCT00325689Phase 4
- Galantamine for Cognition in People With SchizophreniaCompletedNCT00320736Phase 4
- Nicotine Replacement Therapy for Smoking Cessation in SchizophreniaCompletedNCT00320723Phase 4
- Smoking Relapse Prevention in SchizophreniaCompletedNCT00320697Phase 4
- Modafinil as an Adjunctive on Cognitive Functioning in Patients With SchizophreniaCompletedNCT00314639Phase 1/2
- Risperdal Consta and Health Care Utilization in Patients With SchizophreniaCompletedNCT00313391Phase 4
- Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and QuetiapineCompletedNCT00312598
- A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I DisorderCompletedNCT00309686Phase 3
- A Clinical Trial on the Antipsychotic Properties of CannabidiolCompletedNCT00309413Phase 2
- Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode PsychosisCompletedNCT00307216Not applicable
- Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who SmokeCompletedNCT00307203Phase 4
- Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)CompletedNCT00304655Phase 4
- Trial of Cognitive Behavioral Therapy for SchizophreniaStatus unknownNCT00300651Phase 3
- High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective DisorderCompletedNCT00297947Phase 2/3
- A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00297388Phase 3
- A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric PracticesCompletedNCT00292409Phase 3
- Enhancing the Prospective Prediction of PsychosisCompletedNCT00291200
- Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance ImagingCompletedNCT00288340Not applicable
- Study of Amantadine for Weight Stabilization During Olanzapine TreatmentCompletedNCT00287352Phase 1
- Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic MedicationTerminatedNCT00287027
- A Registry of Treatment Adherence for Patients With SchizophreniaCompletedNCT00283517
- Aripiprazole in the Treatment of Acutely Relapsed Patients With SchizophreniaCompletedNCT00283179Phase 3
- Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment OrderTerminatedNCT00282165Phase 4
- Sarcosine Preventive Therapy for Individuals At High Risk for SchizophreniaWithdrawnNCT00276263Phase 2
- Risperidone LA Heathcare Resource StudyCompletedNCT00272597Phase 4
- CARE Study: Improving Treatment for the Most Severely Ill With SchizophreniaCompletedNCT00272584Phase 4
- Brain Imaging and Mental Disorders of Aging InterventionCompletedNCT00267163Phase 4
- Access, Detection and Psychological TreatmentsStatus unknownNCT00260273Not applicable
- Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia PatientsCompletedNCT00255918Phase 1
- Fast Titration Of Quetiapine Versus Currently Approved TitrationCompletedNCT00254813Phase 3
- Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health PopulationCompletedNCT00253240
- A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With SchizophreniaCompletedNCT00253136Phase 3
- A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective DisorderCompletedNCT00253110Phase 4
- A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic SchizophreniaCompletedNCT00249223Phase 3
- A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic PatientsCompletedNCT00249171Phase 4
- A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic SchizophreniaCompletedNCT00249132Phase 3
- A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic SchizophreniaCompletedNCT00249119Phase 3
- Tracking Service Use and Outcomes II:First Episode Psychosis and Psychotic Disorders ClinicTerminatedNCT00248027
- A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With SchizophreniaCompletedNCT00246285Phase 3
- A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar DisorderCompletedNCT00240721Phase 3
- Recovery Therapy TrialCompletedNCT00239122Not applicable
- D-Serine for Enhancing Cognitive Retraining for the Treatment of SchizophreniaCompletedNCT00237848Phase 3
- Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by InjectionCompletedNCT00236548Phase 3
- A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00236457Phase 3
- A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00236379Phase 4
- Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective DisorderCompletedNCT00236353Phase 3
- Efficacy of Galantamine to Treat SchizophreniaTerminatedNCT00232349Phase 4
- Culturally Responsive Person-Centered Care for PsychosisCompletedNCT00231933Phase 1
- Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant SchizophreniaCompletedNCT00231335Phase 4
- Safety Study of ORG 34517 for Major Depression With Psychotic FeaturesCompletedNCT00226278Phase 2
- The Effects of Aripiprazole on Patients With Metabolic SyndromeCompletedNCT00224822Phase 4
- Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective TrialCompletedNCT00224315Phase 4
- Treatment of MDEs During the Course of Psychotic Disorders With DuloxetineCompletedNCT00224302Phase 4
- Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational SkillsCompletedNCT00223418Not applicable
- Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes MellitusCompletedNCT00222807
- A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With SchizophreniaCompletedNCT00222794Phase 4
- A Comparative Study of New Medications for Psychosis in AdolescentsCompletedNCT00222495Not applicable
- Adjunctive Treatment for Decreasing Symptoms of SchizophreniaCompletedNCT00222235Phase 2/3
- A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)CompletedNCT00216632Phase 4
- Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete AdherenceCompletedNCT00215579Phase 4
- A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)CompletedNCT00212797Phase 2
- Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)CompletedNCT00212784Phase 3
- Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)CompletedNCT00212771Phase 3
- Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)TerminatedNCT00211380Not applicable
- Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)TerminatedNCT00211302Not applicable
- A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00210691Phase 3
- Abilify Therapy for Reducing Comorbid Substance AbuseCompletedNCT00208169Phase 4
- A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major DepressionCompletedNCT00208156Phase 3
- Seroquel Therapy for Substance Use Disorders Comorbid With SchizophreniaCompletedNCT00208143Phase 4
- Clinical Estradiol Trial in Women With SchizophreniaCompletedNCT00206570Phase 2
- The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot StudyCompletedNCT00206557Phase 2
- Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?CompletedNCT00206544Phase 2
- Psychological Intervention for Persons in the Early Initial Prodromal StateStatus unknownNCT00204087Phase 3
- Early Pharmacological and Psychological Intervention for Late Prodromal States of PsychosisCompletedNCT00204061Phase 4
- Indicated Prevention of Psychotic Disorders With Low-dose LithiumCompletedNCT00202306Phase 4
- Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic FeaturesCompletedNCT00202293Phase 4
- Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic MedicationCompletedNCT00202280Phase 2/3
- Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic IllnessCompletedNCT00199940Phase 4
- AIMHI NT Relapse Prevention TrialStatus unknownNCT00192582Not applicable
- Dutch Prediction of Psychosis StudyStatus unknownNCT00188981
- The Immune System and Psychiatric DisordersCompletedNCT00184418
- Determining the Safety and Effectiveness of Olanzapine in Children and AdolescentsTerminatedNCT00183612Not applicable
- Improving Primary Care in Patients With Mental DisordersCompletedNCT00183313Phase 3
- Olanzapine Versus Clozapine in Treatment Refractory SchizophreniaCompletedNCT00179231Not applicable
- Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar DisorderCompletedNCT00179062Not applicable
- Serotonin 1A Agonists and Cognition in SchizophreniaCompletedNCT00178971Phase 3
- Improving Outcome in Schizophrenia Through Identification of Genetic Risk FactorsCompletedNCT00178932Not applicable
- Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With PravastatinCompletedNCT00177580Phase 4
- L-carnosine for SchizophreniaCompletedNCT00177177Not applicable
- Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social AnxietyCompletedNCT00177008Phase 4
- V3: Vancouver-Victoria Valacyclovir Trial for Early PsychosisCompletedNCT00175513Phase 2
- Treatment of Depression With QuetiapineTerminatedNCT00174603Phase 3
- Treatment of Major Depressive Disorder With Psychotic Features.TerminatedNCT00174590Phase 3
- Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With RisperidoneCompletedNCT00174200Not applicable
- Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative SymptomsCompletedNCT00169988Not applicable
- Health Care Management and Rehabilitation Skills Training for Treating Serious Mental Illness in Older PeopleCompletedNCT00169052Not applicable
- Alcoholism and Schizophrenia: Effects of ClozapineTerminatedNCT00169026Phase 4